Amplia Therapeutics Limited (ASX:ATX) Annual Report 2020



The latest annual report of Amplia Therapeutics Limited (ATX) was published on 31 Mar 2020. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - ATX Annual Results

Amounts in AUD

Total Revenue
34.23k
Gross Profit
-88.99k
EBIT
-2.22M
Net Tangible Assets
667.83k
Net Income
-2.22M
Capital Expenditures
-

ATX Income Statement 2020 Annual Report

As per the latest Income Statement of ATX, the Net revenue decreased by $-16247 (-32%) compared to the previous period. The operating income in 2020 decreased by $-332948 (-18%). The net income as per the annual report was -2.22M which decreased by $-349516 (-19%) compared to previous year.

Income Statement Report (2020/2019)

20202019
Total Revenue34.23k50.47k
Gross Profit-88.99k-105k
Operating Income-2.22M-1.89M
Income Before Tax-2.22M-1.87M
Net Income-2.22M-1.87M

Balance Sheet - ATX 2020 Annual Report

Read further: ATX Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Amplia Therapeutics Limited showed the company reduced the cash on balance sheet by $-132794 (-11%). The Net tangible assets of ATX on the balance sheet were at 667.83k which is $-58710 (-8%) less than previous annual report. The total stockholder equity also decreased by $-58710 (-1%) compared to previous reporting period.

Balance Sheet Statement Report (2020/2019)

20202019
Cash1.11M1.24M
Total Assets9.12M 9.19M
Long Term Debt--
Total Liabilities510.62k 526.86k
Total Shareholder Equity8.61M8.66M
Net Tangible Assets667.83k726.54k

Cash Flow Statement - ATX 2020 Annual Report

The 2020 annual cash flow statement of Amplia Therapeutics Limited showed that the net income decreased by $-349516 (-19%) compared to previous reporting period. Also the capital expenditure of ATX increased by $NaN (NaN%).

As of 2020, the total cash from investing activities was - and total cash from financing activities was 1.96M.

Cash Flow Statement Report (2020/2019)

20202019
Net Income-2.22M-1.87M
Capital Expenditures--3.19k
Dividends Paid--
Total Cash From From Investing Activities--3.19k
Total Cash From From Financing Activities1.96M-12.14k

Amplia Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202031 Mar 201931 Mar 201831 Mar 2017
Total Revenue34.23k50.47k580.29k1.8M
Cost Of Revenue123.22k155.48k102.69k205.47k
Gross Profit-88.99k-105k477.6k1.59M
Research Development1.07M678.42k3.22M6.04M
Selling General Administrative858.89k860.83k1.55M1.76M
Non Recurring----
Other Operating Expenses---62.55k-33.18k
Total Operating Expenses2.26M1.94M4.9M8.94M
Operating Income-2.22M-1.89M-4.32M-7.14M
Total Other Income Expense Net3.72k20.28k26.97k61.19k
Ebit-2.22M-1.89M-4.32M-7.14M
Interest Expense----
Income Before Tax-2.22M-1.87M-4.3M-7.08M
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-2.22M-1.87M-4.3M-7.08M
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income-2.22M-1.87M-4.3M-7.08M
Net Income Applicable To Common Shares-2.22M-1.87M-4.3M-7.08M

Balance Sheet Statement

Balance Sheet Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202031 Mar 201931 Mar 201831 Mar 2017
Cash1.11M1.24M2.23M5.76M
Net Receivables34.23k-412.01k1.57M
Other Current Assets10.89k-2.47k9.55k
Total Current Assets1.18M1.25M2.64M7.37M
Property Plant Equipment7971.6k-162.22k
Intangible Assets7.94M7.94M--
Total Assets9.12M9.19M2.64M7.54M
Accounts Payable474.07k394.13k1.14k88.17k
Other Current Liab10.61k10.61k10.61k10.28k
Total Current Liabilities510.62k526.86k279.42k907.87k
Total Liab510.62k526.86k279.42k907.87k
Common Stock132.9M130.95M123.02M123.02M
Retained Earnings-122.93M-120.92M-120.3M-116.78M
Treasury Stock-1.37M-1.36M-350.31k389.35k
Other Stockholder Equity-1.37M-1.36M-350.31k389.35k
Total Stockholder Equity8.61M8.66M2.36M6.63M
Net Tangible Assets667.83k726.54k2.36M6.63M
Long Term Debt----

Cash Flow Statement

Cash Flow Statement history of Amplia Therapeutics Limited (ASX:ATX)

31 Mar 202031 Mar 201931 Mar 201831 Mar 2017
Net Income-2.22M-1.87M-4.3M-7.08M
Depreciation8011.59k20.16k36.95k
Change To Netincome205.58k230k160.29k928.47k
Change To Account Receivables-58.65k403.58k1.2M71.38k
Change To Liabilities-16.24k247.44k-628.45k-122.48k
Total Cash From Operating Activities-2.09M-987.35k-3.55M-6.16M
Other Cashflows From Financing Activities-191.48k-12.14k-12.91k-201.93k
Total Cash From Financing Activities1.96M-12.14k-12.91k8.72M
Effect Of Exchange Rate-2.75k14.4k25.68k56.17k
Change In Cash-132.79k-988.28k-3.53M2.56M
Issuance Of Stock2.15M2.15M2.15M8.92M
Capital Expenditures--3.19k-4.42k-46.53k
Dividends Paid----
Total Cashflows From Investing Activities--3.19k1.86k-46.53k